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Abstract
Systemic hypertension increases cardiac workload and subsequently induces signaling networks in heart that underlie
myocyte growth (hypertrophic response) through expansion of sarcomeres with the aim to increase contractility. However,
conditions of increased workload can induce both adaptive and maladaptive growth of heart muscle. Previous studies
implicate two members of the AP-1 transcription factor family, junD and fra-1, in regulation of heart growth during
hypertrophic response. In this study, we investigate the function of the AP-1 transcription factors, c-jun and c-fos, in heart
growth. Using pressure overload-induced cardiac hypertrophy in mice and targeted deletion of Jun or Fos in
cardiomyocytes, we show that c-jun is required for adaptive cardiac hypertrophy, while c-fos is dispensable in this
context. c-jun promotes expression of sarcomere proteins and suppresses expression of extracellular matrix proteins.
Capacity of cardiac muscle to contract depends on organization of principal thick and thin filaments, myosin and actin,
within the sarcomere. In line with decreased expression of sarcomere-associated proteins, Jun-deficient cardiomyocytes
present disarrangement of filaments in sarcomeres and actin cytoskeleton disorganization. Moreover, Jun-deficient hearts
subjected to pressure overload display pronounced fibrosis and increased myocyte apoptosis finally resulting in dilated
cardiomyopathy. In conclusion, c-jun but not c-fos is required to induce a transcriptional program aimed at adapting heart
growth upon increased workload.
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Introduction
Systemic arterial hypertension, valvular pathologies as well as
myocardial infarction represent exceedingly frequent clinical
manifestations contributing to heart failure and/or malignant
ventricular arrhythmias [1]. Initially, these abnormalities and
associated mechanical stress as well as hormonal changes induce
an orchestrated signaling network in the heart that underlies
myocyte growth through expansion of sarcomeres to increase
contractility as well as activation of stress and fetal gene programs.
In the long term, however, these mechanisms may trigger
pathologic remodeling of the myocardium ultimately leading to
heart dilation and reduced cardiac performance [2,3]. Cardiomy-
ocyte apoptosis/necrosis and progressive interstitial fibrosis are
hallmarks that contribute to ventricular wall thinning and
chamber dilation [4]. The latter alterations are also frequently
found in dilated and hypertrophic cardiomyopathies of genetic
origin that are caused by mutations in sarcomeric genes that
constitute the contractile apparatus of cardiac muscle cells [5].
The Mitogen-Activated-Protein-Kinase (MAPK) family repre-
sents an essential signaling module in heart that converts
extracellular stimuli, in particular mechanical stress and hormonal
inputs, into subsequent cellular responses [6,7]. MAPK signaling
consists of a kinase cascade with a tripartite build-up that typically
culminates in dual phosphorylation and activation of p38, c-Jun
N-terminal kinases and extracellular-signal-regulated kinases
(ERKs) [8]. Loss- and gain-of-function experiments in mice
addressing single components of the MAPK signaling cascade
revealed distinct phenotypes in heart. Enhanced signaling through
ERKs led to concentric cardiac hypertrophy with maintained
cardiac function [9,10]. Increased p38 and JNK activity in heart,
obtained by cardiomyocyte-specific constitutive expression of their
respective upstream kinases, resulted in cardiac fibrosis and
ventricular dilation in early adulthood [11–13]. In contrast, loss
of JNK and p38 signaling led to increased cardiac growth at
baseline, as well as in response to pressure-overload [14,15].
Another recent study has demonstrated that specific loss of JNK1
promoted cardiomyocyte apoptosis and transient cardiac deteri-
oration in the early response to pressure overload [16]. Interest-
ingly, heart-restricted deletion of p38a in mice caused proliferation
of adult mammalian cardiomyocytes [17].
MAPK signaling converges into early immediate activation of
several transcription factors including myocyte enhancer factor 2
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(MEF2) as well as Activator Protein-1 (AP-1). The role of MEF2
in cardiac development and stress adaptation has been exten-
sively explored [18]. In contrast, the role of AP-1 in these
processes remains largely unknown. AP-1 comprises a homo or
heterodimeric complex that is composed of basic leucine zipper
(bZIP) proteins that are subdivided into families of the Jun (c-jun,
junB and junD), Fos (c-fos, fosB, fra-1 and fra-2) and the
activating transcription factor ATF (ATFa, ATF2, LRF1/ATF3,
ATF4 and B-ATF) [19]. Early-immediate up-regulation of AP-1
in response to cardiac hypertrophic stimuli has been reported
already in nineties [20–23]. But only recently, first evidence for a
requirement of AP-1 in the adult heart in vivo has been provided
using mice that lack and/or ectopically express junD and fra-1,
respectively [24,25]. Preceding in vitro studies have mainly
focused on the role of c-jun and c-fos in cardiomyocyte growth,
two principal factors that are activated by JNK and ERK,
respectively. In several of these studies, c-jun and c-fos have been
suggested to be required for induction of fetal gene expression
and cardiomyocyte hypertrophy in response to different stimuli
[26–31]. However, studies confirming a requirement of these two
transcription factors in these processes in vivo are still lacking.
We now provide genetic evidence in vivo, employing striated
muscle-restricted deletion of Jun and Fos in mice, that both
transcription factors are not essential for postnatal cardiac
hypertrophy as well as heart growth in response to mechanical
pressure overload. Remarkably however, we found that deletion of
Jun but not of Fos resulted in progressive myocardial fibrosis,
cardiomyocyte apoptosis and changes in sarcomeric organization.
These alterations were exacerbated in response to mechanical
pressure overload resulting in premature heart failure. Conclu-
sively, while c-fos appears to be redundant in heart function, c-jun
specifically counteracts pathologic remodeling of the heart
subjected to pressure overload.
Materials and Methods
Ethics statement
All procedures involving animals were approved by the
‘‘Veterina¨ramt des Kantons Zu¨rich’’ (approval number 150/
2006), and conform to the relevant regulatory standards.
Generation of JunDmu and FosDmu mice
Floxed Jun and Fos mice (Junf/f and Fosf/f mice) have been
generated by the laboratory of Prof Erwin F. Wagner as previously
described [32,33]. Mice harboring deletion of Jun or Fos in striated
muscle (JunDmu or FosDmu) were obtained by crossing Junf/f or Fosf/f
mice with mice carrying Cre recombinase under the control of the
creatine kinase promoter (MCK-Cre) [34]. Resulting experimental
mice were in a mixed 129/Ola-C57BL/6 background and
littermates were used for experiments.
Mouse experiments
Age- (8- to 12-week-old) and weight- (22–26 g) matched mice in
a mixed 129/Ola-C57BL/6 background were subjected to
transverse-aortic constriction (TAC) through constriction of the
descending aorta using a 27 Gauge needle as previously described
[35]. Mice were anesthetized with ketamin/xylazine (2 mg/20 g
and 0.2 mg/20 g, respectively) i.p. and analgized with Temgesic
(0.003 mg/20 g) i.m. Mice were monitored for 6 weeks after
surgery, sacrificed and heart and body weights were determined.
Heart functions were assessed by echocardiography 5.5 weeks
after surgery. The numbers of experimental animals are indicated
in respective figure legends. Reproducibility of the induction of
pressure overload by TAC performed by experimenters was
previously verified [36].
Southern blotting and PCR
Genomic DNA was extracted from heart, skeletal muscle and
liver of Fosf/f and FosDmu mice, and from heart, skeletal muscle and
kidney of Junf/f and JunDmu mice, according to a standard protocol.
20 mg of genomic DNA was digested with XbaI yielding a 6.9 kb
fragment for the floxed Jun allele and a 3.3 kb fragment for the
deleted Jun allele. For detection of the bands, a 0.6 kb BamHI
fragment from the Jun promoter region was used as a probe [37].
20 mg of genomic DNA was digested with HindIII yielding a
6.3 kb fragment for the floxed Fos allele and a 2.9 kb fragment for
the deleted Fos allele. For detection of the bands, a 0.8 kb BamHI/
XbaI EGFP fragment was used as a probe. PCR analysis of
genomic DNA isolated from various organs of Jun+/+, Junf/f and
JunDmu yielded a 297 bp band corresponding to the wild type
alleles, a 344 bp band for the floxed alleles and a 450 bp for the
deleted alleles. PCR analysis of genomic DNA isolated from
various organs of Fos+/+, Fosf/f and FosDmu yielded a 333 bp band
corresponding to the wild type alleles, a 433 bp band for the floxed
alleles and a 1042 bp for the deleted alleles.
Echocardiography
Echocardiography was performed as previously described [38].
Briefly, echocardiographic measurements of mice were carried out
using an ATL HDI 5000 ultrasound device (Philips Medical
Systems) equipped with a 12 MHz phase array linear transducer
(L-12-5). M-mode images were used for measurements of IVSd,
IVSs, LVPWd, LVPWs, LVIDd, and LVIDs. Fractional shorten-
ing (FS) and Ejection Fraction (EF) were calculated using the
formulas: FS (%) = [(LVIDd – LVIDs)/LVIDd]6100; EF (%) =
[(LV Vold – LV Vols)/LV Vold]6100.
Mouse neonatal cardiomyocyte culture
Mouse neonatal hearts were isolated as previously described
[24]. Briefly, cardiac ventricles were fragmented, digested with
ADS buffer containing collagenase (Worthington Biochemical
Corp.) and pancreatin (Sigma), and plated in plating medium
containing 65% DMEM (Animed), 17% M199 (Animed), 10%
Horse Serum (Invitrogen), 5% Fetal Calf Serum (Invitrogen), 2%
L-Glutamine (Animed), 1% PS (Invitrogen). After 24 h, medium
was changed to maintenance medium (86% DMEM, 10% M199,
1% Horse Serum, 2% L-Glutamine, 1% PS).
Histology and TUNEL Assay
Hearts were fixed in a 4% formalin solution (Medite) for 24 h at
+4uC, embedded in paraffin, and cross-sections of 5 mm thickness
were prepared. Sections were stained with H&E or Elastin van
Gieson using standard protocols. Sections were also used for
TUNEL assays (terminal deoxynucleotide transferase-mediated
dUTP nick end labeling) (Roche) to assess the number of apoptotic
cells. The staining was performed according to the manufacturer’s
instructions. The number of apoptotic cells on sections was related
to the total heart area on the respective slides. Three independent
sections per mouse were analyzed.
Immunofluorescence and immunochistochemistry
Immunofluorescence and immunohistochemistry on paraffin
sections, as well as immunofluorescence on isolated mouse
neonatal cardiomyocytes were performed according to standard
protocols. The following antibodies were used: a-c-Jun (BD
Transduction Laboratories), a-Collagen IV (Cedarlane), a-Perios-
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tin (Abcam), a-Actinin 1 (Sigma), a-Titin (kind gift of Dr. E. Ehler,
Randall Institute, King’s College London, England), a-b-Catenin
(kind gift of Dr. E. Ehler Randall Institute, King’s College
London, England).
Western blotting
Western blotting using total heart extracts was performed
according to standard procedures. The following antibodies were
used: a-c-fos (Santa Cruz), a-c-jun (Santa Cruz), a-GFP (Santa
Cruz), a-phospho-Smad2 (Cell Signaling), a-Smad2 (Cell Signal-
ing), a-Periostin (Abcam), a-Myotilin (Santa Cruz), a-Tubulin
(Sigma), a-GAPDH (Sigma), a-Actin (Sigma).
Gelatin zymography
Gelatin zymography of total heart proteins was performed as
previously described with minor adaptations [39]. Briefly, samples
(100 mg of proteins) were mixed with Laemmli sample loading
buffer without b-mercaptoethanol and without boiling were
loaded on 10% SDS-polyacrylamide gels containing 2 mg/ml
gelatin type A from porcine skin (Sigma). After electrophoresis,
gels were washed 2 times for 30 minutes in 2.5% Triton X-100 to
allow proteins to renature, and then for 10 minutes in 100 mM
Tris-HCl pH 7.4. Gels were then incubated at 37uC overnight in
developing buffer (50 mM Tris-HCl, pH 7.5, 10 mM CaCl2,
1 mmol/L ZnCl2). Last, to reveal zones of lysis, gels were stained
for 30 minutes with 0.5% Coomassie blue R250 and destained for
4 hours with 40%:10% v:v methanol:acetic acid, and then with
5%:7.5% v:v methanol:acetic acid until the stacking gel became
colorless.
Quantitative RT-PCR
RNA was purified from total hearts using TRIzol Reagent
(Invitrogen) according to manufacturer’s instructions. 5 mg of
RNA was used as a template to synthesize cDNA, using Ready-
To-Go You-Prime First-Strand Beads (Amersham). Quantitative
RT-PCR reactions were set up as recommended by the
manufacturer (Roche) and were run and analyzed using the
Roche LightCycler 480 system.
Affymetrix gene expression profiling
Affimetrix gene expression profiling was performed in collab-
oration with Functional Genomic Center Zu¨rich. Total RNA
was extracted from the hearts of 10 weeks old Junf/f (n = 2) and
JunDmu (n = 2) mice using TRIzol Reagent (Invitrogen). The
quality of the RNA was determined with a NanoDrop ND 1000
(NanoDrop Technologies) and a Bioanalyzer 2100 (Agilent). 1 mg
of RNA was reverse-transcribed into double-stranded cDNA with
One-Cycle cDNA Synthesis Kit (Affymetrix), purified using a
Sample Cleanup Module (Affymetrix) and then in vitro tran-
scribed in presence of biotinlabeled nucleotides using IVT
Labeling Kit (Affymetrix). Then, biotinylated cRNA was purified
and its quality and quantity was determined, as described above.
5 mg of biotin-labeled cRNA was fragmented randomly to 35–
200 bp and hybridized to GeneChipH GeneChip Mouse
Genome 430 2.0 Arrays. The fluorescent intensity emitted by
the labeled target was measure in Affymetrix GeneChip Scanner
3000 (Affymetrix). Raw data processing was performed using the
Affymetrix AGCC software. Genes with significant expression
difference between 2 knock-out mice and 2 wt were selected,
based on the average knock-out versus wild-type value greater
than 1.3 fold change with a p-value cutoff of 0.05 (using
Student’s t-test) or differential expression of selected genes which
were confirmed by quantitative RT-PCR. The full data set is
available in Gene Expression Omnibus data repository, accession
number: GSE47898.
Statistical analysis
Averaged data are presented as means 6SEM. Statistical
significance was calculated using an ANOVA with post-hoc
Tukey’s test and Student unpaired t test. Significance was accepted
at the level of p,0.05.
Results
Eccentric cardiac hypertrophy upon pressure overload in
mice lacking c-Jun in cardiomyocytes
Based on in vitro studies, the AP-1 transcription factor c-jun has
been suggested to be important in growth and function of the adult
heart [40]. To study its role in cardiomyocytes in vivo, we generated
striated muscle-restricted conditional Jun knockout mice using mice
carrying floxed alleles of Jun that have been crossed to Muscle
Creatine Kinase (MCK)-Cre transgenic mice [33,34]. Southern
blotting and PCR confirmed the appearance of deleted alleles in
hearts and skeletal muscles of floxed Jun mice that were Cre-positive
but not in non-muscle tissues. Cre-negative mice did not reveal any
deletion in hearts and skeletal muscles (Figure 1A and B). An floxed
band (flox) was present in all samples as recombination was not
complete due to the fact that only 30 to 40% of cells in heart and
skeletal muscle are muscle cells. Quantitative RT-PCR andWestern
Blotting, respectively, verified attenuated levels of Jun mRNA and
reduced abundance of c-jun protein in hearts of Cre-positive floxed
mice compared to Cre-negative floxed control mice (Figure 1C and
D). Furthermore, nuclear localization of c-jun protein was detected
in isolated primary neonatal cardiomyocytes of floxed control mice
(here and after referred to as Junf/f mice) but not of conditional Jun
knockout mice (here and after referred to as JunDmumice) confirming
efficient deletion of Jun in cardiomyocytes in vivo (Figure 1E).
JunDmu mice were born at Mendelian frequency and presented
with normal general health, viability, fecundity, body composition
and body weight as compared to control mice (Table S1). To test
if in the absence of c-jun in cardiomyocytes, hearts of these
animals presents increased susceptibility to the pressure induced
heart failure, we subjected mice to mild transaortic constriction
(TAC), a widely used model to induce pressure overload and
cardiac growth [41].
Heart to body weight (H/BW) ratios significantly and similarly
increased in JunDmu and Junf/f mice upon TAC compared to sham-
operated littermates (Figure 2A). H/BW ratios correlated with the
average cross sectional area of cardiomyocytes in situ confirming a
similar growth response in heart upon TAC (Figure S1 A and B).
However, histological cross-sections revealed that hearts of JunDmu
mice were markedly dilated 6 weeks after TAC compared to
hearts of Junf/f that presented with concentric myocardial growth
(Figure 2B). No differences between hearts cross sections of sham-
operated mice of both genotypes were detected. These observa-
tions could be confirmed by echocardiography (Table 1). Indeed,
hearts of both genotypes showed significant muscle growth in
response to TAC as an increase in left ventricular posterior wall
(LVPW) thicknesses was observed. In comparison to sham-
operated mice, left ventricular internal dimensions (LVID) were
significantly decreased upon TAC in Junf/f mice. In contrast, they
were markedly increased in JunDmu mice indicating concentric and
eccentric hypertrophy, respectively. As a consequence, cardiac
performance was impaired in TAC-operated JunDmu mice as
significant decreases in fractional shortening (FS) and ejection
fraction (EF) were observed compared to sham-operated JunDmu
mice and TAC-operated Junf/f mice. No differences in echocar-
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diographic parameters were detected between sham-operated
mice of both genotypes.
Left ventricular remodeling upon TAC entails induction of
hypertrophic marker genes such as for example atrial natriuretic
factor (Anf), brain natriuretic peptide (Bnp), myosin heavy polypep-
tide 7 (Myh7) and skeletal muscle alpha-actin (Acta1). Quantitative
RT-PCR revealed that mRNAs of Anf and Bnp were significantly
increased in TAC-operated hearts of both Junf/f and JunDmu mice
(Figure 2C). Importantly, cardiac expression of Anf and Bnp was
significantly greater in JunDmu compared to Junf/f mice upon TAC.
Interestingly, Anf and Bnp were also significantly enhanced in sham-
operated hearts of JunDmu mice compared to hearts of Junf/f mice. In
contrast, Acta1 was expressed at significantly lower levels in hearts of
JunDmu mice at baseline, and remained low in hearts of JunDmu mice
compared to hearts of Junf/f mice in response to pressure-overload
(Figure 2C). Myh7 was expressed at significantly lower levels in
native hearts of JunDmu mice, but was significantly and similarly
induced in hearts of both JunDmu and Junf/f mice upon TAC
(Figure 2C). These data suggest that deletion of Jun in cardiomy-
ocytes resulted in basal changes in expression of hypertrophic
marker genes without obvious morphological signs of cardiac
hypertrophy and dysfunction. Expression of these genes remained
dramatically altered upon left ventricular pressure-overload and was
associated with maladaptive hypertrophy.
Normal cardiac function in mice lacking Fos in
cardiomyocytes
The AP-1 transcription factor c-fos has also been extensively
discussed as a key player in cardiac function [40]. To study its role
in cardiomyocytes in vivo, we used Fos floxed mice and crossed
them to MCK-Cre transgenic mice. Southern blotting, PCR and
Western blotting confirmed efficient and specific deletion of Fos in
striated-muscle cells (Figure S2 A, B and C). The floxed Fos allele
is generated in the way that its removal leads to GFP expression
[33] that was also detected by Western Blotting in hearts of Cre-
positive floxed mice (Figure S2 C). FosDmu mice were born at
Mendelian frequency and presented with normal general health,
viability, fecundity, body composition and body weight as
compared to Fosf/f mice (Table S2). We subsequently subjected
mice to TAC. H/BW ratios significantly and equally increased in
both Fosf/f and FosDmu mice after TAC compared to sham-operated
mice (Figure S3 A). Histological analyses of heart cross sections
displayed an apparent increase in heart size after TAC compared
to sham-operated mice of both genotypes. Importantly, no
ventricular dilation could be seen in pressure-overloaded FosDmu
and Fosf/f mice (Figure S3 B). These findings were in line with our
subsequent analyses by echocardiography. Sonographic assess-
ment revealed significant and comparable increases of cardiac wall
dimensions upon TAC in FosDmu and Fosf/f mice. FS and EF were
maintained in both genotypes after TAC (Table S3). Quantitative
RT-PCR revealed significant and similar increases of the mRNA
of hypertrophy marker genes in hearts of both genotypes
compared to sham-operated mice. We observed a tendency
towards enhanced induction of these genes in response to TAC in
FosDmu compared to Fosf/f mice, which was however only reaching
significance for Myh7 (Figure S3 C). Thus, deletion of Fos in
cardiomyocytes does not alter cardiac development, postnatal
heart growth as well as cardiac hypertrophy in response to
mechanical pressure overload.
Figure 1. Generation of JunDmu mice. (a) Southern blot analysis of genomic DNA from total heart, skeletal muscle and kidney extracts. Deleted
band (D band) occurs only in samples from MCK-cre positive heart and skeletal muscle. (b) PCR analysis of genomic DNA. PCR in samples from Jun+/+
(+/+), Junf/f (f/f) and JunDmu (f/f Cre) mice yielded a 297 bp band corresponding to the wild type allele, a 344 bp band for the floxed allele and a
450 bp for the D allele. (c) Quantitative RT-PCR. Jun mRNA levels are down-regulated in total heart extracts from JunDmu mice. (d) Western blot
analysis of c-Jun protein levels in total heart extracts of indicated genotypes. (e) Immunofluorescence of isolated mouse neonatal cardiomycoytes.
Nuclear localization of c-Jun can be observed in plated neonatal Junf/f cardiomyocytes, but not JunDmu cardiomyocytes.
doi:10.1371/journal.pone.0073294.g001
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Impaired myocardial remodeling in hearts lacking Jun in
cardiomyocytes
In the following, we addressed cellular mechanisms underlying
premature heart failure in JunDmu mice upon mechanical pressure
overload. Enhanced myocyte loss and cardiac fibrosis are key
factors promoting progression of cardiac hypertrophy to heart
failure [42,43]. An Elastin van Gieson (EvG) stain that allowed for
a better differential analysis of nuclei, connective tissue, muscle
and elastic fibers revealed widespread myocardial fibrosis in hearts
of JunDmu mice, while no foci of apparent collagen deposition were
detectable in hearts of Junf/f 6 weeks after TAC. Fibrosis in hearts
of JunDmu mice was evident already at baseline (in 12 weeks old
JunDmu mice) but was markedly aggravated upon TAC (Figure 3A).
Interstitial fibrosis was associated with increased amounts of
collagen type I (Col1a1), collagen type III (Col3a1) and fibronectin
(Fn) (Figure 3B), all of which are commonly recognized as fibrotic
markers in heart [44–47]. At baseline, JunDmu mice showed
significant up-regulation of Col1a1, Col3a1 and Fn mRNA levels in
native hearts, when compared to Junf/f mice (Figure 3B). TAC
further enhanced the expression of these genes in hearts of JunDmu
mice but not in hearts of Junf/f mice confirming interstitial fibrosis.
Myocardial fibrosis is frequently accompanied by enhanced
cardiomyocyte apoptosis. Indeed, TUNEL staining confirmed
significantly increased numbers of apoptotic cardiomyocytes in
JunDmu mice upon TAC, when compared to sham-operated mice
as well as TAC-operated Junf/f mice. Interestingly, already at
baseline, JunDmu mice showed significantly more TUNEL positive
nuclei in hearts than Junf/f mice. The numbers of apoptotic nuclei
in the hearts of Junf/f mice did not change upon TAC after 6 weeks
(Figure 3C and D).
Several matrix metalloproteinases (Mmps) that have been
identified within the myocardium are dysregulated in heart failure
and transcriptional regulation of Mmps by AP-1 transcription
factors has been reported [43]. Cardiac mRNA levels ofMmp2 and
Mmp14 were significantly upregulated in JunDmu mice upon TAC
Figure 2. Eccentric cardiac hypertrophy in cJunDmu mice upon TAC. (a) H/BW ratios increase of JunDmu and Junf/f mice before and after TAC.
Data are presented as values 6 SEM. (****) p,0.0001; n = 11–12 per group. (b) Histological analyses. H&E staining shows TAC-induced concentric
growth of the heart in Junf/f mice and the heart dilation in JunDmu mice. (c) Relative expression of indicated hypertrophic markers in hearts isolated
from sham or TAC operated Junf/f and JunDmu mice assessed by quantitative RT-PCR. Data are presented as values 6 SEM. (*) p,0.05, (**) p,0.01;
n = 5 per group.
doi:10.1371/journal.pone.0073294.g002
Table 1. Echocardiographic analyses in JunDmu mice after
TAC.
Junf/f JunDmu
Data
measure Sham TAC Sham TAC
HR, bpm 435623 467622 450625 490639
LVPWd, mm 0.7060.002 0.8660.057 # 0.7160.021 0.8560.045 {
LVPWs, mm 0.9360.009 1.1260.032 # 0.9660.018 1.0660.028 {
LVIDd, mm 4.2060.027 3.9860.077 # 4.1360.066 4.5160.253
LVIDs, mm 2.9960.039 2.6960.069 # 2.8260.069 3.5660.280
{1
FS, % 28.8360.62 32.4260.73 # 31.9060.80 21.4662.01
{1
EF, % 55.8460.96 61.2961.08 # 60.3961.20 43.5363.56
{1
All values are shown as mean 6 SEM. n = 5–6 per group. p,0.05 is indicated as:
# WT TAC vs WT sham; { KO TAC vs KO sham; " KO sham vs WT sham; 1 KO
TAC vs WT TAC. HR, Heart rate; LVPWd, Left ventricular posterior wall in diastole;
LVPWs, Left ventricular posterior wall in systole; LVIDd, Left ventricular internal
diameter in diastole; LVIDs, Left ventricular internal diameter in systole; FS,
Fractional Shortening; EF, Ejection Fraction.
doi:10.1371/journal.pone.0073294.t001
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compared to TAC-operated Junf/f and sham-treated mice of both
genotypes (Figure S4 A). Mmp9 mRNA levels were slightly
increased in native hearts of JunDmu compared to Junf/f mice,
however its levels in hearts of TAC operated JunDmu mice were not
altered compared to TAC operated Junf/f hearts (Figure S4 A).
Other cardiac Mmps, Mmp1, Mmp13 and Mmp3 were not found
deregulated (data not shown). Gelatin zymography assays
confirmed that mRNA expression patterns correlated with
activities of Mmp2 and Mmp9 in hearts of both genotypes
(Figure S4 B).
Fibrosis and impairment of the heart function is often associated
with aging. To test if deletion of Jun in heart accelerates aging of
this organ, we stained cross sections of hearts isolated from one
year old JunDmu mice and Junf/f control animals with EvG staining.
We observed minimal progression of fibrosis in hearts of JunDmu
mice while fibrotic remodeling was absent in hearts of control
animals (Figure S5). Consistently, heart function of one year old
JunDmu mice was comparable to the aged matched control animals
as revealed by echocardiography analyzes (Table S4).
Overall, cardiomyocyte-specific deletion of Jun resulted in
deleterious myocardial remodeling that involved increased fibrosis
associated with enhanced degradation of extracellular matrix
protein and programmed cell death leading to premature heart
failure under stress conditions. Although our data indicate that
deficiency of Jun in heart of mice is not sufficient to provoke failure
of this organ up to the age of one year, we cannot exclude that
further aging would result in the impairment of cardiac function in
these animals.
Upregulation of extracellular matrix and downregulation
of cytoskeletal genes in hearts of JunDmu mice
In an attempt to identify specific genes that might be globally
affected in the absence of c-jun in cardiomyocytes, we compared
gene expression in non-stimulated hearts from Junf/f and JunDmu
mice using AffymetrixTM oligonucleotide expression arrays. We
performed these analyzes in non-stimulated conditions as hearts
from JunDmu mice already presented a mild phenotype (increased
fibrosis and altered expression hypertrophic markers) but did not
present functional defects. We obtained a list of 543 genes, with
211 genes up-regulated and 332 genes down-regulated, for which
differential expression was greater or lesser than 1.3 fold in hearts
of JunDmu mice when compared to hearts of Junf/f mice.
Importantly, we analyzed 33 genes by QPCR on the mRNA
isolated from hearts of Junf/f and JunDmu mice and confirmed
deregulation of 18 of them (Table S5). Consistent with marked
fibrosis in hearts of JunDmu mice, we found several extracellular
matrix genes expression of which was increased compared to
hearts of c-Junf/f mice. Among other extracellular matrix genes,
upregulation of periostin, connective tissue growth factor (Ctgf)
and WNT1 inducible signaling pathway protein 1 (Wisp1) were
most interesting, since their involvement in triggering myocardial
fibrosis and heart failure has been previously established [48–52].
Quantitative RT-PCR confirmed that all genes were expressed at
significantly higher levels in sham-operated hearts of JunDmu mice
than in hearts of Junf/f mice (Figure 4 A–C). Although periostin,
Ctgf and Wisp1 expression was significantly enhanced upon TAC
in hearts of both Junf/f and JunDmu mice when compared to sham-
Figure 3. JunDmu mice display impaired myocardial remodeling. (a) Histological analyses. EvG staining reveals mild spontaneous fibrosis in
hearts of JunDmu mice, being markedly enhanced after TAC. (b) Relative expression of indicated fibrotic markers assessed by quantitative RT-PCR in
hearts isolated from sham or TAC operated JunDmu and Junf/f mice. Data are presented as values 6 SEM. (*) p,0.05, (**) p,0.01, (***) p,0.001; n = 5
per group. (c) TUNEL staining of heart cross sections. TAC does not induce apoptosis in hearts of Junf/f mice. JunDmu mice show slightly more
apoptotic cardiomyocytes already at baseline, while the apoptotic rate markedly increased in hearts of JunDmu mice upon TAC. (d) Quantification of
TUNEL positive nuclei does in sham or TAC operated animals of indicated genotypes. Data are presented as values 6 SEM. (*) p,0.05, (**) p,0.01.
doi:10.1371/journal.pone.0073294.g003
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operated mice, their expression in TAC-operated hearts of JunDmu
mice was markedly higher than in hearts of Junf/f mice subjected to
the same procedure. Enhanced periostin expression in sham- and
TAC-operated JunDmu mice could also be confirmed at the protein
level by Western blotting (Figure 4 B). Moreover, immunofluo-
rescence revealed marked deposition of periostin in the intersti-
tium of the myocardium of JunDmu mice, while its accumulation
was not detectable in hearts of Junf/f mice (Figure 4 C).
Most remarkably, 38 of deregulated candidates in hearts from
JunDmu mice were associated with muscle contraction and
cytoskeleton organization. Among them myosin binding protein
C 2 (Mybpc2), myotilin and b-tropomyosin 2 draw our attention
as they are accessory components of the sarcomere [53–55].
Sarcomeres are the principle components of the cardiac contrac-
tile machinery composed of thick and thin filaments [56].
Importantly, sarcomeric organization increases upon hypertrophic
stimuli and its disorganization is often associated with advanced
cardiac hypertrophy and heart failure [57]. We studied in details
the expression of Mybpc2, myotylin and b-tropomyosin 2 by
QPCR in hearts from control Junf/f and JunDmu mice. Expression
of all 3 genes was markedly downregulated in unstimulated hearts
from JunDmu mice compared to unstimulated hearts from Junf/f.
Moreover, their expression was markedly induced in hearts from
Junf/f mice subjected to TAC but not in JunDmu mice on which the
same intervention was performed (Figure 4 D).
Thus, loss of c-Jun in cardiomyocytes leads to deregulation of
several genes that are required for organization of the sarcomere.
c-Jun is also required for their induction upon TAC.
Figure 4. Upregulation of extracellular matrix proteins and downregulation expression of sarcomeric associated proteins in hearts
of JunDmu mice. (a) Expression of indicated genes in hearts of sham or TAC operated mice of indicated genotypes. Data are presented as values 6
SEM. (*) p,0.05, (**) p,0.01, (***) p,0.001, (****) p,0.0001; n = 5 per group. (b) Western blot analyses of Periostin abundancein hearts from sham
and TAC operated JunDmu and Junf/f mice. Tubulin was used as a loading control for the extracts. (c) Immunoflorescence staining for Periostin in cross
sections of hearts from sham and TAC operated animals of indicated genotypes.
doi:10.1371/journal.pone.0073294.g004
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c-jun regulates sarcomere organization
In our microarray expression analysis several genes that encode
for components of the thick and thin filaments were found to be
deregulated in hearts in the absence of Jun in cardiomyocytes. We
therefore hypothesized that deletion of c-jun in cardiomyocytes
affects sarcomere organization. The cultured cardiomyocyte
system is particularly suited to assess sarcomere organization since
morphological changes can be easily recognized since it provides
much higher resolution compared to the in vivo system [57]. We
therefore isolated neonatal cardiomyocytes from JunDmu and Junf/f
mice and performed immunofluorescent stainings using phalloidin
that binds F-actin, as well as antibodies against a-actinin 1 that
localizes to the Z-disc and against M-band titin. Phalloidin staining
revealed a marked disarray of polymerized actin fibers and the
sarcomeric structure appeared rudimentary in cardiomyocytes
isolated from neonatal JunDmu mice. In contrast, actin fibers were
assembled in a more organized fashion into sarcomeres in control
cardiomyocytes (Figure 5A). Sarcomeric a-actinin 1 and M-band
titin stainings displayed a punctuated, thin and rudimentary
sarcomeric structure in cardiomyocytes lacking Jun (Figure 5B),
while control cells showed well-organized sarcomeres. To better
describe the observed phenotype, we defined four categories of
cytoskeleton organization (Figure 5C). 47% of c-jun-deficient
cardiomyocytes presented poorly organized cytoskeleton com-
pared to 11.5% of control cells. Conversely, 27.9% and 37.5% of
control cardiomyocytes presented fully or well organized cytoskel-
eton while only 7.7% and 17.3% of c-Jun deficient cells fell into
these 2 categories, respectively. Similar numbers of c-jun-deficient
and control cardiomyocytes (27.9 and 23.1% respectively)
presented moderately organized cytoskeleton. Overall, the quan-
tification revealed decreased number of cells presenting organized
and increased disorganized cytoskeleton in the absence of c-jun
(Figure 5C).
These results thus support a requirement of c-jun in cytoskeletal
remodeling in cardiomyocytes and provide evidence that changes
in expression profile of genes involved in cytoskeleton organization
in c-jun-deficient cardiomyocytes result in functional changes
observed in mice.
Figure 5. Altered sarcomeric structure of isolated neonatal JunDmu cardiomyocytes. (a) Immunofluorescent staining. Phalloidin staining
shows defects in structural organization of JunDmu cardiomyocytes as compared to Junf/f cardiomyocytes. (b) Immunofluorescent staining. alpha
actinin (aActinin) and titin staining show disruption of Z-line and M-band struture in JunDmu cardiomyocytes as compared to Junf/f cardiomyocytes. (c)
Relative percent of cardimyocytes presenting different cytoskeleton organization: blue bars – fully organize cytoskeleton, red – well organized, yellow
– moderately and green – poorly organized cytoskeleton.
doi:10.1371/journal.pone.0073294.g005
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Discussion
Our data demonstrate that c-Jun is necessary for maintenance
of proper organization of cytoskeleton and sarcomeric structure in
cardiomyocytes and protects the heart from pathologic remodeling
and thus from heart dilation and heart failure, in particular under
stress conditions.
c-jun and c-fos are members of the AP-1 transcription factor
family. Both transcription factors have been previously shown to
be upregulated upon mechanical and pharmacological hypertro-
phic stimuli [23,24,58]. However, functional relevance for this
regulation has not been evidenced thus far. Our results indicate
that c-jun is required for maintaining heart function during a
hypertrophic response, while c-fos is dispensable. The fact that we
did not observe any functional alteration in mice lacking c-fos in
hearts during hypertrophic response might be explained by rapid
upregulation of another member of the AP-1 family, fra-1 upon
hypertrophic stimuli [24]. In fact, a previous study demonstrated
that fra-1 can rescue bone development defects of c-fos-deficient
mice indicating that the function of these 2 proteins might be
partially redundant [59]. Moreover, fra-1 deficiency in heart does
not alter the hypertrophic response [24], further supporting the
possibility that functions of c-fos and fra-1 might be redundant in
heart.
Previous studies implicated c-jun N-terminal kinase (JNK) in
maintaining heart function after mechanical pressure overload
[16,60]. JNK activates c-jun transcriptional activity by promoting
its phosphorylation [8]. Interestingly, deletion of JNK1 or the
upstream kinase Mitogen-activated protein kinase kinase kinase
(MEKK1) resulted in a maladaptive response to TAC. Specifically,
in the absence of JNK1 or MEKK1 hearts subjected to TAC
prematurely decompensated due to an increase in cardiomyocytes
apoptosis. We obtained similar results in hearts of JunDmu mice
subjected to TAC as compared to control hearts. Therefore, our
results indicate that the MEKK1–JNK1 signaling cascade might
promote heart function upon TAC, at least partially, by activating
c-jun.
In an attempt to globally identify targets of c-jun in heart, we
have also performed expression arrays. Among other putative
targets of c-jun, we identify extracellular matrix proteins periostin,
Wisp1 and Ctgf being increased in the absence of c-jun in hearts.
Expression of these 3 genes was further enhanced in c-Jun
deficient hearts subjected to TAC. Importantly, expression of these
genes has been previously implicated in the regulation of heart
function [48–52]. In particular periostin has been broadly
discussed in the context of heart function. Whether it promotes
cardiomyocytes proliferation and cardiac healing after infarction
remains the matter of debate [48,52,61]. Importantly, however,
periostin was shown to promote heart dilation [51]. Therefore the
increase of periostin expression and protein levels in c-jun-deficient
hearts might contribute to heart failure. Unfortunately, with
present data, we cannot answer if c-Jun directly promotes
periostin, Wisp1 and Ctgf expression, or whether increased
expression of these three genes was an indirect consequence of
heart dysfunction caused by loss of c-jun in cardiomyocytes.
Expression arrays revealed that genes involved in regulation of
sarcomere organization constitute a group of other potential c-jun
transcriptional targets. Particularly, expression of Mybpc2,
myotilin and b-tropomyosin 2 were found downregulated in the
hearts of JunDmu mice compared to hearts of Junf/f mice. Moreover,
expression of these genes in JunDmu hearts was not increased upon
TAC like in hearts from control animals. Likewise, based on our
results we cannot determine whether c-jun regulates these genes in
a direct or indirect fashion. However, the c-jun-dependent control
of genes involved in regulation of sarcomere organization
prompted us to investigate the cytoskeleton and sarcomere
structure functionally. Remarkably, c-jun-deficient cardiomyo-
cytes presented disarrangement of sarcomeres and cytoskeleton.
Disarrangement of sarcomeres is a hallmark of advanced heart
hypertrophy and heart failure, while rapid hypertrophic stimuli
increase cytoskeleton and sarcomeres organization [57]. Here, we
thus identified a new transcription factor required for proper
expression of components of the sarcomeric machinery and
therefore for sarcomere function.
In addition to the identification of new cellular functions of c-
jun in regulation of sarcomeres organization, our work revealed
that deletion of c-jun in cardiomyocytes is associated with
increased rate of apoptosis and fibrosis in heart. Depending on
the cell type, c-jun has been reported to prevent or to promote
apoptosis. In neuronal cells c-jun is required for induction of
apoptosis. In contrast, c-jun is necessary for survival of hepato-
blasts, hepatic tumor cells and its deletion potentiates UV and
TNFa induced apoptosis of mouse embryonic fibroblasts
[19,37,62–64]. Major mechanism of c-jun mediated suppression
of apoptosis is by attenuating expression of pro-apoptotic protein
p53 and its target gene noxa [37]. Interestingly, recent studies point
towards p53 as a central molecule in mediating cardiomyocyte
apoptosis and heart failure (for review see [65]). Although in our
study deletion of Jun in heart was restricted to cardiomyocytes,
based on our results we cannot define whether deletion of Jun
promotes apoptosis of cardiomyocytes directly or rather cardio-
myocytes deficient for this protein secrete factor/-s which
promotes apoptosis of the neighboring cells in heart. Defined role
of c-jun in suppressing apoptosis in other cell types in cell
autonomous manner would implicate that c-jun might suppress
apoptosis of cardiomyocytes directly. Based on our results we
cannot point out the potential pro-apoptotic factor secreted by Jun
deficient cardiomyocytes. Secreted proteins identified in our study
as being upregulated in the absence of c-jun in cardiomyocytes
(Periostin, Wisp1 and Ctgf) had been implicated previously as a
factors rather protecting cells from apoptosis [66–71] and their
increased expression in the absence of c-jun might represent
mechanism to counteract apoptosis of the heart cells. Similarly, in
our system we cannot define whether fibrosis observed in the
absence of c-jun in cardiomyocytes is a consequence of increased
apoptosis of these cells or rather increased secretion of fibrogenic
mediators by c-jun deficient cardiomyocytes.
In conclusion, our study led to the identification of c-jun as a
new transcription factor preventing cytoskeleton dysfunction, loss
of cardiomyocytes and cardiac fibrosis, which constitute hallmarks
of maladaptive cardiac growth leading to heart dilation and
failure.
Supporting Information
Figure S1 Quantification of cardiomyocyte cross-sec-
tional area. (A) Immunochistochemical staining of heart cross-
sections for collagen IV. (B) Quantification of cardiomyocyte cross-
sectional area (CSA). Cardiomyocytes from Junf/f and JunDmu mice
showed a similar increase in cross-sectional area (CSA) after TAC.
Data are presented as values 6 SEM. (**) p,0.01; 5 mice per
group were analyzed 1000 cardiomyocytes per mouse were
quantified.
(TIF)
Figure S2 Generation of FosDmu mice. (A) Southern blot
analysis of genomic DNA from total heart, skeletal muscle and
liver extracts. Deleted band (D) occurs only in MCK-cre positive
samples from heart and skeletal muscle, while floxed band (flox) is
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present in all samples. (B) PCR analysis of genomic DNA. PCR in
samples from Fos+/+ (+/+), Fosf/f (f/f) and FosDmu (f/f Cre) mice
yielded a 333 bp band corresponding to the wild type alleles, a
433 bp band for the floxed alleles and a 1042 bp for the deleted
alleles. (C) Western blot analysis of c-Fos protein levels in total
heart extracts. Significant decrease of c-Fos is seen in hearts from
FosDmu mice as compared to Fosf/f mice. Expression of Cre-
recombinase in the heart leads to expression of GFP. Actin was
used as a loading control.
(TIF)
Figure S3 FosDmu mice show concentric heart hypertro-
phy upon TAC. (A) H/BW ratio increases significantly in both
Fosf/f and cFosDmu mice upon TAC. Data are presented as values 6
SEM. (*) p,0.05; n = 4–6 per group. (B) Histological analyses.
H&E staining of heart cross-sections shows slight increase in left-
ventricle wall thickness in both TAC-operated groups. (C) Relative
expression of hypertrophic markers assessed by quantitative RT-
PCR. Anf, Bnp, Acta1, and Myh7 are re-expressed in hypertrophied
hearts of Fosf/f and FosDmu mice. (*) p,0.05, (**) p,0.01, (***)
p,0.001, (****) p,0.0001; n= 4–6 per group.
(TIF)
Figure S4 TAC-induced cardiac fibrosis in JunDmu mice
is associated with enhanced MMPs expression and
activity. (A) Relative expression of myocardial MMPs (as
indicated) assessed by quantitative RT-PCR, in sham and TAC
operated mice from indicated genotypes. Data are presented as
values 6 SEM. (*) p,0.05, (**) p,0.01; n= 5 per group. (B)
Gelatin zymography on total heart protein extracts. TAC-
operated JunDmu mice show greatly increased activity of MMP-2
(arrow at 66 kDa), and slightly decreased activity of MMP-9
(arrow at 92 kDa) in hearts as compared to sham-operated mice
and TAC-operated Junf/f mice. No difference in MMP-2 and
MMP-9 activity in hearts is observed between TAC operated Junf/f
mice, when compared to sham-operated controls, as well as sham-
operated Junf/f and JunDmu mice.
(TIF)
Figure S5 Hearts of one year old JunDmu mice present
spontaneous fibrosis. (A) Normal H/BW ratio of one year old
JunDmu mice. (B) Histological analyses. EvG staining reveals
spontaneous fibrosis in hearts of one year old JunDmu mice.
(TIF)
Table S1 Body and organs weights in adult JunDmu mice
and corresponding control mice.
(DOC)
Table S2 Body and organs weights in adult FosDmu mice
and corresponding control mice.
(DOC)
Table S3 Echocardiographic analyses in FosDmu mice
after TAC.
(DOC)
Table S4 Echocardiographic assessment of heart func-
tion in one year old JunDmu and corresponding control
mice.
(DOC)
Table S5
(XLSX)
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